Moreover, MM patients with SRRM2 positive expression on plasma cells had a higher incidence of 1q21 amplification, which is a common secondary cytogenetic abnormality associated with poor prognosis, drug resistance, and disease progression [23]. Here, SRRM2 is linked to Miyoshi myopathy.